Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental drugs
SM-130686
Другие языки:

    SM-130686

    Подписчиков: 0, рейтинг: 0
    SM-130686
    SM-130,686 skeletal.svg
    Clinical data
    ATC code
    • none
    Identifiers
    • (+)-(3S)-3-(2-chlorophenyl)-1-[2-(diethylamino)ethyl]-3-hydroxo-2-oxo-4-(trifluoromethyl)indoline-6-carboxamide
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    Chemical and physical data
    Formula C22H23ClF3N3O3
    Molar mass 469.89 g·mol−1
    3D model (JSmol)
    • FC(F)(F)c3c1c(cc(c3)C(N)=O)N(CCN(CC)CC)C(=O)C1(O)c2ccccc2Cl
    • InChI=1S/C22H23ClF3N3O3/c1-3-28(4-2)9-10-29-17-12-13(19(27)30)11-15(22(24,25)26)18(17)21(32,20(29)31)14-7-5-6-8-16(14)23/h5-8,11-12,32H,3-4,9-10H2,1-2H3,(H2,27,30)/t21-/m1/s1
    • Key:YSSPGXCFFITNCE-OAQYLSRUSA-N
      (verify)

    SM-130686 is a small-molecule drug which acts as a potent, orally-active agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) and growth hormone secretagogue, with around half the potency of the endogenous agonist ghrelin as a stimulator of growth hormone release. It produces dose-dependent increases in muscle mass and decrease in body fat, and is under investigation for the treatment of growth hormone deficiency and other medical conditions. Concerns about its potential use as a performance-enhancing drug for athletes have led to the development of urine tests for SM-130686 and other GHSR agonists, even though no drugs from this class have yet progressed to clinical use.

    See also


    Новое сообщение